Explore /
Poster
/ A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab-refractory esophagogastric (EG) cancer.

A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab-refractory esophagogastric (EG) cancer.

Authors

Yelena Yuriy Janjigian

Memorial Sloan-Kettering Cancer Center, New York, NY

Yelena Yuriy Janjigian , Marinela Capanu , Tooba Imtiaz , David Paul Kelsen , Geoffrey Yuyat Ku , Mark Schattner , Karen T. Brown , David H. Ilson , David B. Solit , Michael F. Berger , Efsevia Vakiani

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2014 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Translational Research

Clinical Trial Registration Number

NCT01522768

Citation

J Clin Oncol 32, 2014 (suppl 3; abstr 52)

DOI

10.1200/jco.2014.32.3_suppl.52

Abstract #

Poster Bd #

B26

Abstract Disclosures

Similar Posters

Poster

2015 Gastrointestinal Cancers Symposium

$A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab refractory esophagogastric (EG) cancer.$